Prescription drug · NDA
Etoposide NDC 83270-451
Etoposide 50 mg/1 · Capsule · Oral · Onesource Specialty Pharma Limited
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 83270-451-05 | 83270045105 | 20 CAPSULE in 1 CARTON (83270-451-05)Marketed from May 29, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Etoposide
- Generic name (nonproprietary)
- etoposide
- Active ingredients
- Etoposide — 50 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 019557
- Marketing start
- Listing expires
- Other FDA classes
- Topoisomerase Inhibitors (Mechanism)
- Identifiers
- Product ID 83270-451_5744cb93-0a8c-19ca-e063-6294a90aecd6SPL ID 5744cb93-0a8c-19ca-e063-6294a90aecd6SPL set ID 7bc994df-ee84-4ed7-80fa-737f70918953RxCUI 197687UNII 6PLQ3CP4P3
- Pharmacologic class
- Topoisomerase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N483270045105followed by a unit qualifier and the quantityPackage 83270-0451-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
INDICATIONS AND USAGE Etoposide is indicated in the management of: Small Cell Lung Cancer —Etoposide capsules in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer.
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 019557
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| VePesidetoposide | Etoposide 50 mg/1 | CapsuleOral | Amneal Pharmaceuticals NY LLC | 69238-2811 |